Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
NCT ID: NCT01544569
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarkers in samples from young patients with rhabdoid tumors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
NCT01553175
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
NCT01453465
Studying Biomarkers in Samples From Younger Patients With Kidney Cancer
NCT01642095
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To investigate the expression and function of transposons in 50 primary rhabdoid tumors.
OUTLINE: Freshly frozen rhabdoid tumors will be studied using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR) to establish the genomic location of transposons. Protein expression in rhabdoid tumor tissue microarrays is also analyzed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
fluorescence in situ hybridization
gene expression analysis
gene mapping
microarray analysis
polymerase chain reaction
protein expression analysis
laboratory biomarker analysis
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Freshly frozen rhabdoid tumors from either renal or extra-renal sites from children younger than 2 years of age
* Clinical patient information (age, gender, comorbidities, tumor stage, size, pathology, therapy, outcome) available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth A. Mullen, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AREN12B3
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000727229
Identifier Type: OTHER
Identifier Source: secondary_id
AREN12B3
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00689
Identifier Type: REGISTRY
Identifier Source: secondary_id
AREN12B3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.